At a glance
ClinicalIndex Comparison Record- ✓Confirmed non-small cell lung cancer (Stage I)
- ✓Age > 18 years
- ✓Accessible tumor suitable for serial core biopsies
- ✓Adequate organ and marrow function
- ✕Prior thoracic radiation in the region to be treated
- ✕Concurrent investigational agents or chemotherapy
- ✕Concurrent or prior immunotherapy
- ✕Systemic steroids within 14 days before radiation through post-SABR biopsies
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Studying the Pathologic and Immunologic Response After Ablative Radiation in Stage I Non-Small Cell Lung Cancer
In Brief
A clinical study evaluating Post-SABR Biopsy for Non-small Cell Lung Cancer Stage I. Completed, enrolled 6 participants across 1 site.
Detailed Summary
This is a pilot study to compare pre- and post-SABR core biopsies of stage I NSCLC tumors to identify SABR-induced immune-mediated tumor recognition based on a significant and specific expansion of T-cell clones using a novel T-cell receptor (TCR) sequencing assay. This will be coupled with (1) novel genomic analysis of candidate tumor antigens that may be released from the pre-SABR tumor and (2) functional validation assays to screen post-treatment peripheral blood T-cells for reactivity to these released candidate tumor antigens. In addition, cell-based analysis will be used to identify changes in key T-cell infiltrates into the post-SABR tumor.
Study Details
Timeline
Interventions
Post-SABR Biopsy